versión impresa ISSN 0025-7680
Medicina (B. Aires) vol.71 no.4 Ciudad Autónoma de Buenos Aires jul./ago. 2011
Prevalence of Janus kinase 2 mutations in patients with unusual site venous thrombosis
Ana Lisa Basquiera1, Aldo H. Tabares1, Néstor Soria2, Miriam Salguero3, Ricardo Ryser4, Juan José García1
1Hospital Privado Centro Médico de Córdoba,
2Facultad de Ciencias Médicas, Universidad Nacional de Córdoba,
3Clínica Vélez Sarsfield, Córdoba,
Postal address: Dra. Ana L. Basquiera, Servicio de Hematología y Oncología, Hospital Privado Centro Médico de Córdoba, Naciones Unidas 346, 5016 Córdoba, Argentina
Fax: (54-351) 4688270 e-mail: email@example.com
We aimed to study patients with splanchnic vein thrombosis (SVT) and cerebral vein thrombosis (CVT) searching for JAK2 mutations. We evaluated 14 patients (median age: 41.5 years) with portal vein thrombosis (PVT) = 7; mesenteric vein thrombosis (MVT) = 3; and CVT = 4. JAK2 V617F was assessed by allele specific PCR of peripheral blood DNA. In addition, DNA was sequenced for other JAK2 mutations. Other inherited and acquired thrombophilia risk factors were evaluated. JAK2 V617F was positive in four out of seven patients with PVT and in one CVT patient. These five patients had a diagnosis of myeloproliferative disorder (MPD) at the moment of the occurrence of thrombosis (n = 2) or later (n = 2). Patients with MVT and CVT were negative for JAK2 V617F, except one patient with CVT and a diagnosis of essential thrombocythemia. No other JAK2 mutations were found in this cohort. Besides MPD, other thrombophilia risk factors were identified in five patients. One patient had MPD as well as thrombophilia risk factor. In this group, 4 out of 7 of the patients with PVT carried the JAK2 V617F mutation with or without overt MPD. However, the investigation of other JAK2 mutations may not be necessary in patients with thrombosis at unusual sites.
Key words: JAK2; Myeloproliferative disorders; Thrombosis; Thrombophilia
Prevalencia de las mutaciones del gen quinasa Janus 2 en pacientes con trombosis venosa en sitios poco frecuentes. Nuestro objetivo fue estudiar pacientes con trombosis de las venas esplácnicas (TVE) o trombosis de las venas cerebrales (TVC) en búsqueda de mutaciones del gen quinasa Janus 2 (JAK2). Se estudiaron 14 pacientes (media de edad: 41.5 años) con trombosis de la vena porta (TVP n = 7), trombosis de la vena mesentérica (TVM, n = 3) y TVC (n = 4). La mutación V617F del gen JAK2 fue evaluada por reacción en cadena de la polimerasa (PCR) alelo-específica en muestras de sangre periférica. Además, se realizó secuenciación de ADN en búsqueda de otras mutaciones del gen JAK2 distintas de V617F. También se investigaron factores genéticos y adquiridos para trombofilia. JAK2 V617F fue positiva en 4 de 7 pacientes con TVP y en un paciente con TVC. Estos 5 pacientes con la mutación tuvieron diagnóstico de síndrome mieloproliferativo (SMP) en el momento de la detección de la trombosis (n = 2) o después (n = 3). Un paciente con TVP sufrió el episodio trombótico 18 años después del diagnóstico del SMP y la mutación JAK2 V617F fue negativa. No se encontraron otras mutaciones del gen JAK2 en este grupo d e pacientes. Además del diagnóstico de SMP, se identificaron otros factores de riesgo para trombofilia en 4 pacientes. Un paciente tuvo un factor de riesgo para trombofilia además del diagnóstico de SMP. La mutación JAK2 V617F se presentó en 4/7 de los pacientes con TVP con o sin un diagnóstico obvio de SMP. La investigación de otras mutaciones podría no ser necesaria en pacientes con trombosis en sitios poco frecuentes.
Palabras clave: JAK2; Síndrome mieloproliferativo; Trombosis; Trombofilia
Phi negative myeloproliferative disorders (MPD) are common causes of thrombosis outside the lower extremities, such as splanchnic vein thrombosis (SVT; hepatic, portal, mesenteric or splenic) or cerebral vein thrombosis (CVT)1. In fact, in 28 to 49% of the patients with hepatic vein thrombosis (HVT) and in 14 to 35% of the patients with extrahepatic portal vein thrombosis (PVT), an underlying MPD can be identified2, 3. Conversely, 5 to 10% of the patients with MPD may have SVT thrombosis along the course of the disease and 1% of the patients with essential thrombocythemia (ET) can present with CVT4, 5. However, the prevalence of underlying MPD has been variable depending on the diagnostic criteria used2. Also, MPD may not be apparent at the moment of the thrombotic event ("latent MPD") but fully develop several years later ("overt MPD")1.
In 2005, a somatic mutation in the Janus Kinase 2 gene (JAK2), exon 14, was described for most of the patients with PV and for around half of the patients with ET and/or IMF. This mutation results in a valine to phenylalanine substitution at position 617 in the autoinhibitory domain of JAK2 tyrosine kinase, leading to the constitutive activation of the protein, which in turn promotes cellular growth independently of exogenous growth factors, and the activation of intracellular activation pathways, such as STAT5. Several techniques based on the polymerase chain reaction (PCR) have been described for mutation detection in clinical practice, being the allele specific PCR the more sensitive one6-8.
Although there is conflicting evidence about the importance of JAK2 V617F mutation in predicting the risk of thrombosis in patients with MPD, two recent meta-analyses have strongly suggested that JAK2 V617F positivity in patients with ET could be associated with increased risk of thrombosis9, 10. Interestingly, this association may be stronger in cases of thrombosis at unusual venous sites11. Thus, JAK2 V617F has been proposed as a marker of MPD in patients with SVT, independently of other MPD criteria11, 12. Besides JAK2 V617F, other JAK2 mutations have been reported13. However, its prevalence in JAK2 V617F negative MPD patients with unusual site venous thrombosis has not been completely addressed.
We aimed to study the occurrence of JAK2 V617F and other JAK2 mutations in a series of patients with splanchnic and cerebral venous thrombosis.
Materials and Methods
We retrospectively screened 14 patients with documented splanchnic and cerebral vein thrombosis, who were referred to our institution for comprehensive thrombophilia testing. Diagnosis of thrombosis occurred between 1985 and 2009. We included patients with or without overt MPD. Laboratory tests searching for hereditary and acquired risk factors for thrombosis were performed in all patients, including genotyping for factor V Leiden and 20210A prothrombin gene allele, measurement of antithrombin, proteins C and S, screening for antiphospholipid antibodies and assay for total homocysteine levels. MPD was diagnosed according to WHO criteria14. Complete clinical data were obtained, including acquired risk factors. We registered date of thrombosis, diagnosis of MPD, treatment received and recurrence of thrombosis. All patients were managed with anticoagulants after the thrombotic event. Patients were followed up until December 31 2009 or death.
The screening for exon 14 JAK2 V617F mutation was per - formed with allele-specific PCR on DNA of peripheral blood, as previously published6. In patients negative for V617F mutation, we sequenced genomic DNA with primers designed to amplify the coding region exons 12 to 19, and intron/exon boundaries of JAK2 gene. The PCR products were sequenced directly in both directions with automatic sequencer and the sequences were manually analyzed. DNA extraction and PCR studies were performed at the School of Medicine of Universidad Nacional de Córdoba.
The Hospital Privado Institutional Review Board approved the study and all patients gave written informed consent to participate in this study.
We studied 14 patients (median age 41.5 years; range 8 to 70) with SVT or CVT. Median follow-up since diagnosis of the thrombotic event was 48.7 months (range 6.8 to 303.3 months). Clinical characteristics and results of thrombophilia tests are shown in Table 1.
TABLE 1.- Characteristics of patients with splanchnic or cerebral vein thrombosis (n = 14)
*MPD = myeloproliferative disorder; F = female; M = male; PVT = portal venous thrombosis; MVT = mesenteric venous thrombosis; CVT = cerebral vein thrombosis; ET = essential thrombocythemia; PMF = primary myelofibrosis; APL = antiphospholipids; HyH = hyperhomocysteinemia; FVL = factor V Leiden; PCD = Protein C Deficiency; AC = anticoagulation; HU = hydroxyurea.
† These patients had also splenic vein thrombosis.
Ten out of 14 patients had splanchnic venous thrombosis and five of them had a diagnosis of MPD: four patients with ET and one patient with primary myelofibrosis (PMF). Four patients had cerebral venous thrombosis and only one of them had a diagnosis of MPD (ET = 1). Two out of six patients had a diagnosis of MPD at the occurrence of the venous thrombotic event (overt MPD), other three patients after the thrombotic event (five years, one year and three months, respectively) and finally, one patient with PMF had the thrombotic event after 18 years of MPD diagnosis. Overall, JAK2 V617F was positive in five out of 14 patients (35.71%). In patients with a diagnosis of MPD, JAK2 V617F was positive in 5 out of 6 (overt MPD = 2; latent MPD = 3); the remaining patient with PMF and JAK2 V617F negative was receiving thalidomide (fourth months) when the thrombosis occurred.
The three patients whose thrombosis developed before MPD diagnosis (latent MPD) had recurrent episodes, even though they were taking oral anticoagulant treatment. Two out of three patients received hydroxyurea when MPD was diagnosed and no further thrombotic events were registered. The other three patients with almost simultaneous diagnosis of thrombosis and MPD (overt MPD) received hydroxyurea from the beginning and no recurrences of thrombosis were registered until end of follow-up. All patients are currently alive.
Four out of 14 patients (28.6%) had one thrombophilia risk factor in the laboratory investigations (Table 1). One of these patients also had JAK2 positive MPD. Transient risk factors for thrombosis were registered in only one patient who had received treatment with thalidomide the four months before the thrombotic event (patient number 7). Also, one patient had a diagnosis of diabetes mellitus prior to the thrombotic event (patient number 11).
Our series contributes to confirm that a substantial proportion of patients with SVT have JAK2 V617F mutation with no other JAK2 mutation in the settings of SVT and CVT. In patients with SVT, the presence of portal hypertension, occult blood loss, hypersplenism or hemodilution can mask signs that help to diagnose MPD. Also, some patients may have "latent MPD"12. Therefore, JAK2 V617F has become a useful tool in the diagnostic approach of patients with SVT. At least 10 series of patients with thrombosis at unusual sites have reported the prevalence of JAK2 V617F mutation in this setting11, 12, 15-20. In SVT, the rate of mutation was between 17 and 74%, with most of the series having rates of about 30-40%. Along these series, the precise prevalence of MPD is difficult to assess, since the diagnostic criteria have been variable. For this reason, JAK2 V617F mutation was common in patients with overt MPD at the time of the SVT, ranging from 71-100%, depending on the type of MPD diagnosed (100% for PV and 71% for others)12. However, this mutation was also observed in patients without MPD at the time of thrombosis (0-32%). In a longer follow-up of these patients some may develop classical features of MPD and in fact, some authors report a diagnosis of MPD as late as 8 years after the thrombotic event. In our series, three JAK2 positive patients had a diagnosis of MPD a long time after the thrombotic event. Interestingly, patients with isolated mesenteric thrombosis in our series were JAK2 negative and did not develop MPD in a mean follow-up of 63.5 months, as previously described11, 16.
Only one patient with CVT had an overt MPD and JAK2 V617F was positive. Literature data about CVT and JAK2 mutations are scarce. The largest series studied 45 patients with CVT and four cases had overt MPD at thrombosis diagnosis with a JAK2 V617F prevalence of 75% (3/4)11.
In our patients with thrombosis at unusual sites, we did not find other JAK2 mutations. Colaizzo et al have described 2 patients with PV presenting with splanchnic venous thrombosis and exon 12 JAK2 mutation13. However, no mutation of JAK2 exon 12 has been reported in other large series of patients with abdominal venous thrombosis, either by direct sequencing or by using allele-specific PCR12, 21, 22. Although Siemiatkowska et al. found three novel mutations in JAK2 exons 12, 19 and 25 in V617F-negative patients with MPD no data about thrombosis were provided23.
In conclusion, JAK2 V617F is frequently found in patients with splanchnic vein thrombosis and may be considered marker of latent MPD. No other mutations of JAK2 appear to be important in this setting.
Acknowledgements: This study was supported by a grant from the Florencio Fiorini Foundation and the Argentine Medical Association.
Conflict of interest: The authors declare no competing financial interests.
1. Austin SK, Lambert JR. The JAK2V617F mutation and thrombosis. Br J Haematol 2008; 143: 307-20. [ Links ]
2. Chait Y, Condat B, Cazals-Hatem D, et al. Relevance of the criteria commonly used to diagnose myeloproliferative disorders in patients with splanchnic vein thrombosis. Br J Haematol 2005; 129: 553-60. [ Links ]
3. Briere JB. Budd-Chiari syndrome and portal vein thrombosis associated with myeloproliferative disorders: diagnosis and management. Semin Thromb Hemost 2006; 32: 208-18. [ Links ]
4. Bazzan M, Tamponi G, Schinco P, et al. Thrombosis-free survival and life expectancy in 187 consecutive patients with essential thrombocythemia. Ann Hematol 1999; 78: 539-43. [ Links ]
5. Stam J. Thrombosis of the cerebral veins and sinuses. N Engl J Med 2005; 352: 1791-8. [ Links ]
6. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutations of the tyrosine kinase JAK2 en human myeloproliferative disorders. Lancet 2005; 365: 1054-61. [ Links ]
7. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythemia vera. Nature 2005; 434: 1144-8. [ Links ]
8. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779-90. [ Links ]
9. Ziakas PD. Effect of JAK2 V617F on thrombotic risk in patients with essential thrombocythemia: measuring the uncertain. Haematologica 2008; 93:9-11. [ Links ]
10. Dahabreh IJ, Zoi K, Giannouli S, Zoi C, Loukopoulos D, Voulgarelis M. Is JAK2 V617F mutation more than a diagnostic index? A meta-analysis of clinical outcomes in essential thrombocythemia. Leuk Res 2009; 33: 67-73. [ Links ]
11. De Stefano V, Fiorini A, Rossi E, et al. Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders. J Thromb Haemost 2007; 5: 708-14. [ Links ]
12. Kiladjian JJ, Cervantes F, Leebeek FW, et al. The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis. A report on 241 cases. Blood 2008; 111: 4922-9. [ Links ]
13. Colaizzo D, Amitrano L, Tiscia GL, Grandone E, Guardascione MA, Margaglione M. A new JAK2 gene mutation in patients with polycythemia vera and splanchnic vein thrombosis. Blood 2007; 110: 2768-9. [ Links ]
14. Pierre R, Lea NC, Thiele J, Vardiman JW, Brunning RD, Flandrin G. Pathology and genetics of tumors of haematopoietic and lymphoid tissues. In: Jaffe ES, Harris NL, Stein H, Vardman JW (eds). The World Health Organization classification of tumors. Lyon: IARC Press; 2001, pp.32-44. [ Links ]
15. Boissinot M, Lippert E, Girodon F, et al. Latent myeloproliferative disorders revealed by the JAK2-V617F mutation and endogenous megakaryocytic colonies in patients with splanchnic vein thrombosis. Blood 2006; 108: 3223-4. [ Links ]
16. Primignani M, Barosi G, Bergamaschi G, et al. Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology 2006; 44: 1528-34. [ Links ]
17. Regina S, Herault O, Alteroche D, Binet C, Gruel Y. JAK2 V617F is specifically associated with idiopathic splanchnic vein thrombosis. J Thromb Haemost 2007; 5: 859-61. [ Links ]
18. Patel RK, Lea NC, Heneghan MA, et al. Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari Syndrome. Gastroenterology 2006; 130: 2031-8. [ Links ]
19. Goulding C, Uttenthal B, Foroni L, et al. The JAK2 V617F tyrosine kinase mutation identifies clinically latent myeloproliferative disorders in patients presenting with hepatic or portal vein thrombosis. Int Jnl Lab Hem 2008; 30: 415-9. [ Links ]
20. Colaizzo D, Amitrano L, Tiscia GL, et al. Occurrence of the JAK2 V617F mutation in Budd-Chiari syndrome. Blood Coagul Fibrinolysis 2008; 19: 459-62. [ Links ]
21. Bergamaschi GM, Primignani M, Barosi G, et al. MPL and JAK2 exon 12 mutations in patients with the Budd-Chiari syndrome or extrahepatic portal vein obstruction. Blood 2008; 111: 4418. [ Links ]
22. Fiorini A, Chiusolo P, Rossi E, et al. Absence of the JAK2 exon 12 mutations in patients with splanchnic venous thrombosis and without overt myeloproliferative neoplasms. Am J Hematol 2009; 84: 126-7. [ Links ]
23. Siemiatkowska A, Bieniaszewska M, Hellmann A, Limon J. JAK2 and MPL gene mutations in V617F-negative myeloproliferative neoplasms. Leuk Res 2010; 34: 387-9. [ Links ]